House Bill Would Expand Rx Market, But Negatives Draw PhRMA Protest
This article was originally published in The Pink Sheet Daily
Executive Summary
Government negotiation of drug prices for the public plan option and Medicaid-level rebates for dual eligibles (individuals qualifying for Medicare and Medicaid) in Part D would be particularly hard for the industry to swallow.
You may also be interested in...
Rx Contribution To Health Reform May Be $100 Bil. After All, Obama Suggests
What's another $20 billion among friends? Biopharma executives had to cringe when, during his July 22 press conference on health reform, President Obama discussed the industry's pledge to deliver $80 billion in savings to help fund the effort. Not only was there a rough edge to his description of the agreement, the President seemingly upped the amount industry may end up having to put on the table by 25 percent
Rx Contribution To Health Reform May Be $100 Bil. After All, Obama Suggests
What's another $20 billion among friends? Biopharma executives had to cringe when, during his July 22 press conference on health reform, President Obama discussed the industry's pledge to deliver $80 billion in savings to help fund the effort. Not only was there a rough edge to his description of the agreement, the President seemingly upped the amount industry may end up having to put on the table by 25 percent
White House Economic Team Sees Senate As Target To Intervene In Health Reform
President Obama's call to withhold judgment on bills so far translates into seeing Senate Finance Committee agreement as beginning of White House intervention strategy.